Healthcare / Medical DevicesKOSDAQ
$78800.00
+4700.00 (+6.34%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-13.9B · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.92T
P/E
N/A
•EV/EBITDA
N/A
•ROE
-69.7%
↓Gross Margin
53.1%
↑Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+17.6%
FCF CAGR
—
FCF margin
-5.2%
FCF / Net income
0.03x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $85.48B · net income $-138.17B · FCF $-4.47B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $85.48B | $85.48B | $72.03B | $65.93B | $52.57B |
| Net Income | $-138.17B | $-138.17B | $141.60B | $48.36B | $4.54B |
| EBITDA | $-145.93B | $-145.93B | $149.80B | $75.09B | $12.15B |
| EPS | -5810.00 | -5810.00 | 6242.00 | 2096.00 | 200.00 |
| Gross Margin | 53.1% | 53.1% | 49.5% | 51.4% | 51.3% |
| Operating Margin | 5.2% | 5.2% | 5.4% | 12.3% | 18.0% |
| Net Margin | -161.7% | -161.7% | 196.6% | 73.4% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.44 | 0.56 | 0.84 |
| Current Ratio | 0.64 | 0.64 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.47B | $-4.47B | $-13.92B | $-37.12B | $-43.78B |
| Returns | |||||
| ROE | -69.7% | -69.7% | 50.4% | 32.9% | 4.6% |
| Valuation | |||||
| P/E | — | — | 4.34 | 13.10 | 109.00 |
| EV/EBITDA | — | — | 4.81 | 9.33 | 46.98 |
| P/B | 9.45 | 9.45 | 2.19 | 4.31 | 5.06 |
| Growth & Yield | |||||
| Revenue Growth | 18.7% | 18.7% | 9.3% | 25.4% | — |
| EPS Growth | -193.1% | -193.1% | 197.8% | 948.0% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+217.2%
Start / end P/E
n/dx → n/dx
EPS bridge
6242.00 → -5810.00
Residual
+217.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.